Verastem Oncology to Present Long-Term Data on AVMAPKI-FAKZYNJA Combination Therapy for LGSOC
Event summary
- Verastem Oncology will present long-term data from the Phase 2 RAMP 201 trial on its AVMAPKI-FAKZYNJA combination therapy at the SGO 2026 Annual Meeting on April 10-13.
- The data includes an additional year of follow-up beyond the initial presentation, reinforcing the therapy's safety and efficacy for recurrent LGSOC.
- The combination therapy received FDA accelerated approval in May 2025 for KRAS-mutated recurrent LGSOC, contingent upon confirmatory trial results.
- Verastem is conducting the Phase 3 RAMP 301 trial as a confirmatory study for the combination therapy.
The big picture
Verastem Oncology's presentation of long-term data on its AVMAPKI-FAKZYNJA combination therapy comes at a critical juncture for the company, as it seeks to reinforce the therapy's clinical profile ahead of the confirmatory Phase 3 trial. The data could influence the broader adoption of targeted therapies for low-grade serous ovarian cancer (LGSOC), a rare and challenging indication with limited treatment options. The strategic focus on RAS/MAPK pathway-driven cancers positions Verastem within a competitive landscape of precision oncology, where the ability to demonstrate sustained efficacy and safety is paramount.
What we're watching
- Clinical Validation
- Whether the long-term data from the RAMP 201 trial will further solidify the clinical benefit of the AVMAPKI-FAKZYNJA combination therapy.
- Regulatory Pathway
- The pace at which Verastem can complete the Phase 3 RAMP 301 trial and secure full FDA approval for the combination therapy.
- Market Expansion
- How Verastem plans to leverage the data to expand the use of the combination therapy beyond KRAS-mutated recurrent LGSOC.
Related topics